Beskrywing

Cell therapies aims to introduce new, healthy cells into a patient’s body, to replace the diseased or missing ones. Manufacturing them involves collecting a specific set of cells from the blood, modifying them to produce a more vigorous attack on a patient’s cancer cells, and then reinjecting them into the patient. The global cell therapy biomanufacturing market is set to increase by US$ 4.4 miljard van 2022 aan 2028, representing a compound annual growth rate (CAGR) van 8.8% gedurende die voorspellingsperiode.

Die verslag verskaf up-to-date markgrootte data vir tydperk 2018-2021 en voorspel tot 2028 covering key market aspects like sales value for cell therapy biomanufacturing. The global cell therapy biomanufacturing market is segmented on the basis of application, en streek. On the basis of application, the global cell therapy biomanufacturing market has been segmented into bone repair, cancer, cardiovascular diseases, neurological disorders, skeletal muscle repair, ander. Onder hierdie, the skeletal muscle repair segment was accounted for the highest revenue generator in 2021. In terms of geography, the global cell therapy biomanufacturing market has been segmented into Asia Pacific, Europa, Noord-Amerika, MEA (Midde-Ooste en Afrika), Latyns-Amerika. North America is estimated to account for the largest share of the global cell therapy biomanufacturing market.

The global cell therapy biomanufacturing market is highly competitive. Asof 2021, the major players in the global cell therapy biomanufacturing market were Bone Therapeutics S.A., Caladrius Biosciences Inc., Iovance Biotherapeutics Inc., Lonza Group AG, Merck KGaA, Novartis AG, Regen BioPharma Inc., Regeneus Ltd., The Bristol-Myers Squibb Company (BMS).

Die verslag is 'n waardevolle hulpbron vir maatskappye en organisasies wat in hierdie bedryf aktief is. It provides a cohesive picture of the cell therapy biomanufacturing market to help drive informed decision making for industry executives, beleidmakers, akademies, en ontleders.

Verslag Omvang

Toepassing: bone repair, cancer, cardiovascular diseases, neurological disorders, skeletal muscle repair, ander
Streek: Asiatiese Stille-Oseaan, Europa, Noord-Amerika, MEA (Midde-Ooste en Afrika), Latyns-Amerika
Jare oorweeg: hierdie verslag dek die tydperk 2018 aan 2028

Sleutelvoordele vir belanghebbendes

– Get a comprehensive picture of the global cell therapy biomanufacturing market
– Bepaal groeisektore en -neigings vir belegging

INHOUDSOPGAWE

Deel 1. Inleiding
– Omvang van die studie
– Studietydperk
– Geografiese omvang
– Navorsingsmetodologie
Deel 2. Cell therapy biomanufacturing market overview
Deel 3. Markverdeling volgens toepassing
– Bone repair
– Cancer
– Cardiovascular diseases
– Neurological disorders
– Skeletal muscle repair
– Ander
Deel 4. Market breakdown by region
– Asiatiese Stille-Oseaan
– Europa
– Noord-Amerika
– MEA (Midde-Ooste en Afrika)
– Latyns-Amerika
Deel 5. Sleutel maatskappye
– Bone Therapeutics S.A.
– Caladrius Biosciences, Inc.
– Iovance Biotherapeutics, Inc.
– Lonza Group AG
– Merck KGaA
– Novartis AG
– Regen BioPharma, Inc.
– Regeneus Ltd.
– The Bristol-Myers Squibb Company (BMS)
Oor StrategyHelix
Vrywaring